{"pmid":32485894,"title":"In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus.","text":["In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus.","The coronavirus disease, COVID-19, caused by the novel coronavirus SARS-CoV-2, which first emerged in Wuhan, China and was made known to the World in December 2019 turned into a pandemic causing more than 126,124 deaths worldwide up to April 16th, 2020. It has 79.5% sequence identity with SARS-CoV-1 and the same strategy for host cell invasion through the ACE-2 surface protein. Since the development of novel drugs is a long-lasting process, researchers look for effective substances among drugs already approved or developed for other purposes. The 3D structure of the SARS-CoV-2 main protease was compared with the 3D structures of seven proteases, which are drug targets, and docking analysis to the SARS-CoV-2 protease structure of thirty four approved and on-trial protease inhibitors was performed. Increased 3D structural similarity between the SARS-CoV-2 main protease, the HCV protease and alpha-thrombin was found. According to docking analysis the most promising results were found for HCV protease, DPP-4, alpha-thrombin and coagulation Factor Xa known inhibitors, with several of them exhibiting estimated free binding energy lower than -8.00 kcal/mol and better prediction results than reference compounds. Since some of the compounds are well-tolerated drugs, the promising in silico results may warrant further evaluation for viral anticipation. DPP-4 inhibitors with anti-viral action may be more useful for infected patients with diabetes, while anti-coagulant treatment is proposed in severe SARS-CoV-2 induced pneumonia.","Molecules","Eleftheriou, Phaedra","Amanatidou, Dionysia","Petrou, Anthi","Geronikaki, Athina","32485894"],"abstract":["The coronavirus disease, COVID-19, caused by the novel coronavirus SARS-CoV-2, which first emerged in Wuhan, China and was made known to the World in December 2019 turned into a pandemic causing more than 126,124 deaths worldwide up to April 16th, 2020. It has 79.5% sequence identity with SARS-CoV-1 and the same strategy for host cell invasion through the ACE-2 surface protein. Since the development of novel drugs is a long-lasting process, researchers look for effective substances among drugs already approved or developed for other purposes. The 3D structure of the SARS-CoV-2 main protease was compared with the 3D structures of seven proteases, which are drug targets, and docking analysis to the SARS-CoV-2 protease structure of thirty four approved and on-trial protease inhibitors was performed. Increased 3D structural similarity between the SARS-CoV-2 main protease, the HCV protease and alpha-thrombin was found. According to docking analysis the most promising results were found for HCV protease, DPP-4, alpha-thrombin and coagulation Factor Xa known inhibitors, with several of them exhibiting estimated free binding energy lower than -8.00 kcal/mol and better prediction results than reference compounds. Since some of the compounds are well-tolerated drugs, the promising in silico results may warrant further evaluation for viral anticipation. DPP-4 inhibitors with anti-viral action may be more useful for infected patients with diabetes, while anti-coagulant treatment is proposed in severe SARS-CoV-2 induced pneumonia."],"journal":"Molecules","authors":["Eleftheriou, Phaedra","Amanatidou, Dionysia","Petrou, Anthi","Geronikaki, Athina"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32485894","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.3390/molecules25112529","keywords":["dpp-4 inhibitors","hcv protease inhibitors","sars-cov-2","a-thrombin inhibitors","coronavirus","docking","protease inhibitors"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668892169452126208,"score":9.490897,"similar":[{"pmid":32363219,"pmcid":"PMC7195910","title":"Binding site analysis of potential protease inhibitors of COVID-19 using AutoDock.","text":["Binding site analysis of potential protease inhibitors of COVID-19 using AutoDock.","Recent outbreak of COVID-19 caused by SARS-CoV-2 in December 2019 raised global health concerns. Re-purposing the available protease inhibitor drugs for immediate use in treatment in SARS-CoV-2 infections could improve the currently available clinical management. The current study, aims to predict theoretical structure for protease of COVID-19 and to explore further whether this protein can serve as a target for protease inhibitor drugs such as remdesivir, nelfinavir, lopinavir, ritonavir and alpha-ketoamide. While the 3D structure of protease was predicted using SWISS MODEL server, molecular interaction studies between protein and ligands were performed using AutoDock software. The predicted protease model was reasonably good based on reports generated by different validation servers. The study further revealed that all the protease inhibitor drugs got docked with negative dock energy onto the target protein. Molecular interaction studies showed that protease structure had multiple active site residues for remdesivir, while for remaining ligands the structure had only one active site residue each. From the output of multiple sequence alignment, it is evident that ligand binding sites were conserved. The current in silico study thus, provides structural insights about the protease of COVID-19 and also its molecular interactions with some of the known protease inhibitors.","Virusdisease","Mothay, Dipti","Ramesh, K V","32363219"],"abstract":["Recent outbreak of COVID-19 caused by SARS-CoV-2 in December 2019 raised global health concerns. Re-purposing the available protease inhibitor drugs for immediate use in treatment in SARS-CoV-2 infections could improve the currently available clinical management. The current study, aims to predict theoretical structure for protease of COVID-19 and to explore further whether this protein can serve as a target for protease inhibitor drugs such as remdesivir, nelfinavir, lopinavir, ritonavir and alpha-ketoamide. While the 3D structure of protease was predicted using SWISS MODEL server, molecular interaction studies between protein and ligands were performed using AutoDock software. The predicted protease model was reasonably good based on reports generated by different validation servers. The study further revealed that all the protease inhibitor drugs got docked with negative dock energy onto the target protein. Molecular interaction studies showed that protease structure had multiple active site residues for remdesivir, while for remaining ligands the structure had only one active site residue each. From the output of multiple sequence alignment, it is evident that ligand binding sites were conserved. The current in silico study thus, provides structural insights about the protease of COVID-19 and also its molecular interactions with some of the known protease inhibitors."],"journal":"Virusdisease","authors":["Mothay, Dipti","Ramesh, K V"],"date":"2020-05-05T11:00:00Z","year":2020,"_id":"32363219","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1007/s13337-020-00585-z","keywords":["covid-19","coronavirus","molecular docking","protein homology modelling","sars-cov-2"],"locations":["SWISS","ligand"],"countries":["Switzerland"],"countries_codes":["CHE|Switzerland"],"e_drugs":["remdesivir","Lopinavir","Nelfinavir","Ritonavir"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496034668545,"score":534.6647},{"pmid":32406317,"title":"Potential anti-viral activity of approved repurposed drug against main protease of SARS-CoV-2: an in silico based approach.","text":["Potential anti-viral activity of approved repurposed drug against main protease of SARS-CoV-2: an in silico based approach.","The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) which was first reported in Wuhan province of China, has become a deadly pandemic causing alarmingly high morbidity and mortality. In the absence of new targeted drugs and vaccines against SARS-CoV-2 at present, the choices for effective treatments are limited. Therefore, considering the exigency of the situation, we focused on identifying the available approved drugs as potential inhibitor against the promising Coronavirus drug target, the Main Protease, using computer-aided methods. We created a library of U. S. Food and Drug Administration approved anti-microbial drugs and virtually screened it against the available crystal structures of Main Protease of the virus. The study revealed that Viomycin showed the highest -CDocker energy after docking at the active site of SARS-CoV-2 Main Protease. It is noteworthy that Viomycin showed higher -CDocker energy as compared to the drugs currently under clinical trial for SARS-CoV-2 treatment viz. Ritonavir and Lopinavir. Additionally, Viomycin formed higher number of H-bonds with SARS-CoV-2 Main Protease than its co-crystallised inhibitor compound N3. Molecular dynamics simulation further showed that Viomycin embedded deeply inside the binding pocket and formed robust binding with SARS-CoV-2 Main Protease. Therefore, we propose that Viomycin may act as a potential inhibitor of the Main Protease of SARS-CoV-2. Further optimisations with the drug may support the much-needed rapid response to mitigate the pandemic.","J Biomol Struct Dyn","Mahanta, Saurov","Chowdhury, Purvita","Gogoi, Neelutpal","Goswami, Nabajyoti","Borah, Debajit","Kumar, Rupesh","Chetia, Dipak","Borah, Probodh","Buragohain, Alak K","Gogoi, Bhaskarjyoti","32406317"],"abstract":["The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) which was first reported in Wuhan province of China, has become a deadly pandemic causing alarmingly high morbidity and mortality. In the absence of new targeted drugs and vaccines against SARS-CoV-2 at present, the choices for effective treatments are limited. Therefore, considering the exigency of the situation, we focused on identifying the available approved drugs as potential inhibitor against the promising Coronavirus drug target, the Main Protease, using computer-aided methods. We created a library of U. S. Food and Drug Administration approved anti-microbial drugs and virtually screened it against the available crystal structures of Main Protease of the virus. The study revealed that Viomycin showed the highest -CDocker energy after docking at the active site of SARS-CoV-2 Main Protease. It is noteworthy that Viomycin showed higher -CDocker energy as compared to the drugs currently under clinical trial for SARS-CoV-2 treatment viz. Ritonavir and Lopinavir. Additionally, Viomycin formed higher number of H-bonds with SARS-CoV-2 Main Protease than its co-crystallised inhibitor compound N3. Molecular dynamics simulation further showed that Viomycin embedded deeply inside the binding pocket and formed robust binding with SARS-CoV-2 Main Protease. Therefore, we propose that Viomycin may act as a potential inhibitor of the Main Protease of SARS-CoV-2. Further optimisations with the drug may support the much-needed rapid response to mitigate the pandemic."],"journal":"J Biomol Struct Dyn","authors":["Mahanta, Saurov","Chowdhury, Purvita","Gogoi, Neelutpal","Goswami, Nabajyoti","Borah, Debajit","Kumar, Rupesh","Chetia, Dipak","Borah, Probodh","Buragohain, Alak K","Gogoi, Bhaskarjyoti"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32406317","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1080/07391102.2020.1768902","keywords":["covid-19","docking","fda approved drugs","molecular dynamics","mpro","sars-cov-2","viomycin"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Ritonavir","Viomycin","Lopinavir"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666802845383393282,"score":526.1177},{"pmid":32340562,"title":"A Molecular Modeling Approach to Identify Effective Antiviral Phytochemicals against the Main Protease of SARS-CoV-2.","text":["A Molecular Modeling Approach to Identify Effective Antiviral Phytochemicals against the Main Protease of SARS-CoV-2.","The main protease of SARS-CoV-2 is one of the important targets to design and develop antiviral drugs. In this study, we have selected 40 antiviral phytochemicals to find out the best candidates which can act as potent inhibitors against the main protease. Molecular docking is performed using AutoDock Vina and GOLD suite to determine the binding affinities and interactions between the phytochemicals and the main protease. The selected candidates strongly interact with the key Cys145 and His41 residues. To validate the docking interactions, 100 ns molecular dynamics (MD) simulations on the five top-ranked inhibitors including hypericin, cyanidin 3-glucoside, baicalin, glabridin, and alpha-ketoamide-11r were performed. Principal component analysis (PCA) of potential energy components of MD discloses that baicalin, cyanidin 3-glucoside, and alpha-ketoamide-11r have structural similarity with the apo-form of the main protease. These findings are also strongly supported by root-mean-square deviation (RMSD), root-mean-square fluctuation (RMSF), radius of gyration (Rg), and solvent accessible surface area (SASA) investigations. PCA is also used to find out the quantitative structure-activity relationship (QSAR) for pattern recognition of the best ligands. Multiple linear regression (MLR) of QSAR reveals the R(2) value of 0.842 for the training set and 0.753 for the test set. Our proposed MLR model can predict the favorable binding energy compared with the binding energy detected from molecular docking. ADMET analysis demonstrates that these candidates appear to be safer inhibitors. Our comprehensive computational and statistical analysis show that these selected phytochemicals can be used as potential inhibitors against the SARS-CoV-2.","J Biomol Struct Dyn","Islam, Rajib","Parves, Rimon","Paul, Archi Sundar","Uddin, Nizam","Rahman, Md Sajjadur","Mamun, Abdulla Al","Hossain, Md Nayeem","Ali, Md Ackas","Halim, Mohammad A","32340562"],"abstract":["The main protease of SARS-CoV-2 is one of the important targets to design and develop antiviral drugs. In this study, we have selected 40 antiviral phytochemicals to find out the best candidates which can act as potent inhibitors against the main protease. Molecular docking is performed using AutoDock Vina and GOLD suite to determine the binding affinities and interactions between the phytochemicals and the main protease. The selected candidates strongly interact with the key Cys145 and His41 residues. To validate the docking interactions, 100 ns molecular dynamics (MD) simulations on the five top-ranked inhibitors including hypericin, cyanidin 3-glucoside, baicalin, glabridin, and alpha-ketoamide-11r were performed. Principal component analysis (PCA) of potential energy components of MD discloses that baicalin, cyanidin 3-glucoside, and alpha-ketoamide-11r have structural similarity with the apo-form of the main protease. These findings are also strongly supported by root-mean-square deviation (RMSD), root-mean-square fluctuation (RMSF), radius of gyration (Rg), and solvent accessible surface area (SASA) investigations. PCA is also used to find out the quantitative structure-activity relationship (QSAR) for pattern recognition of the best ligands. Multiple linear regression (MLR) of QSAR reveals the R(2) value of 0.842 for the training set and 0.753 for the test set. Our proposed MLR model can predict the favorable binding energy compared with the binding energy detected from molecular docking. ADMET analysis demonstrates that these candidates appear to be safer inhibitors. Our comprehensive computational and statistical analysis show that these selected phytochemicals can be used as potential inhibitors against the SARS-CoV-2."],"journal":"J Biomol Struct Dyn","authors":["Islam, Rajib","Parves, Rimon","Paul, Archi Sundar","Uddin, Nizam","Rahman, Md Sajjadur","Mamun, Abdulla Al","Hossain, Md Nayeem","Ali, Md Ackas","Halim, Mohammad A"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32340562","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1080/07391102.2020.1761883","keywords":["antiviral phytochemicals","covid-19","sars-cov-2","molecular docking","molecular dynamics"],"locations":["hypericin","cyanidin","QSAR"],"e_drugs":["hypericin","glabridin","baicalin","cyanidin 3-O-glucoside"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138495136038914,"score":462.68967},{"pmid":32308266,"pmcid":"PMC7147498","title":"Molecular docking and dynamics simulation of FDA approved drugs with the main protease from 2019 novel coronavirus.","text":["Molecular docking and dynamics simulation of FDA approved drugs with the main protease from 2019 novel coronavirus.","Design and development of an effective drug to combat the 2019 novel coronavirus remains a challenge. Therefore, it is of interest to study the binding features of 1615 FDA approved drugs with the recently known 2019-nCoV main protease structure having high sequence homology with that from SARS-CoV. We document the binding features of top 10 drugs with the target protein. We further report that Conivaptan and Azelastine are mainly involved in hydrophobic interactions with active site residues. Both drugs can maintain close proximity to the binding pocket of main protease during simulation. However, these data need further in vitro and in vivo evaluation to repurpose these two drugs against 2019-nCoV.","Bioinformation","Odhar, Hasanain Abdulhameed","Ahjel, Salam Waheed","Albeer, Ali A Mohammed Ali","Hashim, Ahmed Fadhil","Rayshan, Ali Mahmood","Humadi, Suhad Sami","32308266"],"abstract":["Design and development of an effective drug to combat the 2019 novel coronavirus remains a challenge. Therefore, it is of interest to study the binding features of 1615 FDA approved drugs with the recently known 2019-nCoV main protease structure having high sequence homology with that from SARS-CoV. We document the binding features of top 10 drugs with the target protein. We further report that Conivaptan and Azelastine are mainly involved in hydrophobic interactions with active site residues. Both drugs can maintain close proximity to the binding pocket of main protease during simulation. However, these data need further in vitro and in vivo evaluation to repurpose these two drugs against 2019-nCoV."],"journal":"Bioinformation","authors":["Odhar, Hasanain Abdulhameed","Ahjel, Salam Waheed","Albeer, Ali A Mohammed Ali","Hashim, Ahmed Fadhil","Rayshan, Ali Mahmood","Humadi, Suhad Sami"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32308266","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.6026/97320630016236","keywords":["2019-ncov","docking","dynamics simulation","main protease","repurposing"],"e_drugs":["azelastine","conivaptan"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138491199684608,"score":449.1495},{"pmid":32374074,"title":"Potential anti-SARS-CoV-2 drug candidates identified through virtual screening of the ChEMBL database for compounds that target the main coronavirus protease.","text":["Potential anti-SARS-CoV-2 drug candidates identified through virtual screening of the ChEMBL database for compounds that target the main coronavirus protease.","A novel coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], or 2019 novel coronavirus [2019-nCoV]) has been identified as the pathogen of coronavirus disease 2019 (COVID-19). The main protease (M(pro) , also called 3-chymotrypsin-like protease [3CL(pro) ]) of SARS-CoV-2 is a potential target for treatment of COVID-19. A M(pro) homodimer structure suitable for docking simulations was prepared using a crystal structure (PDB ID: 6Y2G; resolution 2.20 A). Structural refinement was performed in the presence of peptidomimetic alpha-ketoamide inhibitors, which were previously disconnected from each Cys145 of the M(pro) homodimer, and energy calculations were performed. Structure-based virtual screenings were performed using the ChEMBL database. Through a total of 1,485,144 screenings, 64 potential drugs (11 approved, 14 clinical, and 39 preclinical drugs) were predicted to show high binding affinity with M(pro) . Additional docking simulations for predicted compounds with high binding affinity with M(pro) suggested that 28 bioactive compounds may have potential as effective anti-SARS-CoV-2 drug candidates. The procedure used in this study is a possible strategy for discovering anti-SARS-CoV-2 drugs from drug libraries that may significantly shorten the clinical development period with regard to drug repositioning.","FEBS Open Bio","Tsuji, Motonori","32374074"],"abstract":["A novel coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], or 2019 novel coronavirus [2019-nCoV]) has been identified as the pathogen of coronavirus disease 2019 (COVID-19). The main protease (M(pro) , also called 3-chymotrypsin-like protease [3CL(pro) ]) of SARS-CoV-2 is a potential target for treatment of COVID-19. A M(pro) homodimer structure suitable for docking simulations was prepared using a crystal structure (PDB ID: 6Y2G; resolution 2.20 A). Structural refinement was performed in the presence of peptidomimetic alpha-ketoamide inhibitors, which were previously disconnected from each Cys145 of the M(pro) homodimer, and energy calculations were performed. Structure-based virtual screenings were performed using the ChEMBL database. Through a total of 1,485,144 screenings, 64 potential drugs (11 approved, 14 clinical, and 39 preclinical drugs) were predicted to show high binding affinity with M(pro) . Additional docking simulations for predicted compounds with high binding affinity with M(pro) suggested that 28 bioactive compounds may have potential as effective anti-SARS-CoV-2 drug candidates. The procedure used in this study is a possible strategy for discovering anti-SARS-CoV-2 drugs from drug libraries that may significantly shorten the clinical development period with regard to drug repositioning."],"journal":"FEBS Open Bio","authors":["Tsuji, Motonori"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32374074","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1002/2211-5463.12875","keywords":["2019-ncov","covid-19","drug repositioning","mpro","sars-cov-2","virtual screening"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496321978368,"score":439.68948}]}